Table 3 Comparison of treatment-related adverse events between the modified XELOX and standard XELOX groups
Adverse events | standard XELOX (n = 126, %) | modified XELOX (n = 84, %) | P value |
|---|---|---|---|
Neurotoxicity | |||
 Total | 96 (76.2) | 33 (39.3) | < 0.001 |
  Grade 1 | 61 (48.4) | 20 (23.8) | < 0.001 |
  Grade 2 | 31 (24.6) | 11 (13.1) | 0.041 |
  Grade 3–4 | 4 (3.2) | 2 (2.4) | 0.311 |
Leucopenia | |||
 Total | 88 (69.8) | 45 (53.6) | 0.017 |
  Grade 1 | 56 (44.4) | 29 (34.5) | 0.196 |
  Grade 2 | 22 (17.5) | 10 (11.9) | 0.329 |
  Grade 3–4 | 10 (7.9) | 6 (7.1) | 0.832 |
Thrombocytopenia | |||
 Total | 75 (59.5) | 32 (38.1) | 0.011 |
  Grade 1 | 45 (35.7) | 17 (20.2) | 0.016 |
  Grade 2 | 26 (20.6) | 12 (14.3) | 0.242 |
  Grade 3–4 | 4 (3.2) | 3 (3.6) | 0.592 |
Nausea/vomiting | |||
 Total | 46 (36.5) | 26 (31.0) | 0.861 |
  Grade 1 | 27 (21.4) | 13 (15.5) | 0.221 |
  Grade 2 | 18 (14.3) | 10 (11.9) | 0.683 |
  Grade 3–4 | 1 (0.8) | 3 (3.6) | 0.149 |
Diarrhea | |||
 Total | 17 (13.5) | 11 (13.1) | 0.934 |
  Grade 1 | 9 (7.1) | 7 (8.3) | 0.794 |
  Grade 2 | 5 (4.0) | 3 (3.6) | 0.883 |
  Grade 3–4 | 3 (2.4) | 1 (1.2) | 0.536 |
Hand-foot syndrome | |||
 Total | 50 (39.7) | 23 (27.4) | 0.067 |
  Grade 1 | 32 (25.4) | 15 (17.9) | 0.238 |
  Grade 2 | 13 (10.3) | 5 (6.0) | 0.128 |
  Grade 3–4 | 5 (4.0) | 3 (3.6) | 0.251 |
Hepatic disorder | |||
 Total | 46 (36.5) | 22 (26.2) | 0.134 |
  Grade 1 | 34 (27.0) | 17 (20.2) | 0.325 |
  Grade 2 | 10 (7.9) | 4 (4.8) | 0.414 |
  Grade 3–4 | 2 (1.6) | 1 (1.2) | 0.817 |